Materials that can produce electricity are at the core of piezoelectric research and the vision of self-powering machines and devices. Nanotechnology researchers are even pursuing nanopiezotronics devices that have the potential of converting biological mechanical energy, acoustic/ultrasonic vibration energy, and biofluid hydraulic energy into electricity, demonstrating a new pathway for self-powering of wireless nanodevices and nanosystems. In addition to miniaturizing piezoelectric devices down to the nanoscale, nanotechnology is also contributing to making next-generation devices more effective. Piezoelectric ceramics for instance generate electrical charge or voltage when they experience stress/strain, and thus are highly efficient at converting mechanical energy into electrical energy. However, ceramics are rigid, which greatly limits the applicability of the energy harvesting. Researchers have now demonstrated that high performance piezoelectric ceramics can be transferred in a scalable process onto rubber or plastic, rendering them flexible without any sacrifice in energy conversion efficiency.
Multifunctional nanoparticles are at the core of a growing field called theranostics that develops technologies physicians can use to diagnose and treat diseases in a single procedure. The major promise of theranostics is to bring together key stages of a medical treatment, such as the diagnosis and therapy, and thus to make a treatment shorter, safer and more efficient. Theranostic approaches require adequate tools with a high multi-functionality and selectivity. The initial phase of the development of theranostics has already revealed the two general challenges: lack of multifunctional methods and agents, and the lack of selectivity and specificity of available agents - that ultimately requires cell and molecular levels. Researchers have now developed a novel method based on gold nanoparticle-generated transient photothermal vapor nanobubbles, a structure they refer to as plasmonic nanobubbles.
About two years ago we reported on the concept of a biological nanofactory that comprises multiple functional modules: a targeting module specifically targets cells; a sensing module senses and transports raw materials that are present in their vicinity; a biosynthesis module converts raw materials to useful molecules, transport them back to the cell surface, and self-destructs upon completion of this sequence (self-destruct module).
Scientists at the University of Maryland have now demonstrated what was conceptualized in this earlier vision. Moreover they have added a quality that was not originally conceived - the nanofactory needs to have modalities that enable its own assembly. The scientists used the principles of synthetic biology to create the enzyme pathway that has as a part of it an assembly domain. Then, they used 'biofabrication' to assemble antibodies on to the synthesis domain, which enables targeting.
With all the buzz that is being created by portable e-book readers, it's worth taking a look at one of the advanced display technologies - also often referred to as electronic paper - that make these devices happen. Unlike a conventional flat panel display, which uses a power-consuming backlight to illuminate its pixels, electronic paper reflects light like ordinary paper and is capable of holding text and images indefinitely without drawing electricity, while allowing the image to be changed later. Because they can be produced on thin, flexible substrates an due to their paper-like appearance, electrophoretic displays are considered prime examples of the electronic paper category. Electrophoretic displays already are in commercial use, for instance in the Kindle or in the Sony Reader, but so far the displays are mostly black and white. There are still cost and quality issues with color displays. New work by researchers in South Korea shows that organic ink nanoparticles could provide an improved electronic ink fabrication technology resulting in e-paper with high brightness, good contrast ratio, and lower manufacturing cost.
Scientists have great expectations that nanotechnologies will bring them closer to the goal of creating computer systems that can simulate and emulate the brain's abilities for sensation, perception, action, interaction and cognition while rivaling its low power consumption and compact size. DARPA for instance has a program called SyNAPSE that is trying to develop electronic neuromorphic machine technology that scales to biological levels. Started in late 2008 and funded with $4.9 million, the goal of the initial phase of the SyNAPSE project is to 'develop nanometer scale electronic synaptic components capable of adapting the connection strength between two neurons in a manner analogous to that seen in biological systems, as well as, simulate the utility of these synaptic components in core microcircuits that support the overall system architecture.' Independent from this military-inspired research, nanotechnology researchers in France have developed a hybrid nanoparticle-organic transistor that can mimic the main functionalities of a synapse. This organic transistor, based on pentacene and gold nanoparticles and termed NOMFET (Nanoparticle Organic Memory Field-Effect Transistor), has opened the way to new generations of neuro-inspired computers, capable of responding in a manner similar to the nervous system.
Carbon-supported catalysts are widely used in many applications. For example, platinum nanoparticles supported on bulk carbon frameworks are used as fuel cell electrodes. The obvious challenge is to have a large area of carbon surface so that the catalyst particles can be dispersed without any aggregation. Graphene with its 2D nanostructure provides a large surface area (theoretically, the surface area of graphene is about 2600 square meters per gram) to anchor catalyst particles. Scientists have now succeeded in dispersing two different types of nanoparticles - silver and titanium dioxide - on a reduced graphene oxide at different sites without any aggregation.
In a nanotechnology risk assessment study published last year, researchers concluded that the costs associated with nanomaterial risk assessment in the United States alone could range anywhere from $249 million to $1.18 billion and might take decades to complete at current levels of investment in nano-hazard testing. While research in quantitative risk characterization of nanomaterials is crucially important, and no one advocates abandoning this approach, scientists and policy makers must face the reality that many of these knowledge gaps cannot be expected to be closed for many years to come - and decision making will need to continue under conditions of uncertainty. At the same time, current chemical-based research efforts are mainly directed at establishing toxicological and ecotoxicological and exposure data for nanomaterials, with comparatively little research undertaken on the tools or approaches that may facilitate near-term decisions. A group of scientists suggests that this situation requires a significant research program in a fundamental area of timely, yet informed decision making regarding the potential risks of nanomaterials. They highlight some of these issues as well as outline some of the currently available tools and approaches for decision making regarding the potential risks of nanomaterials.
Oncogenes are genes that are associated with the development of cancer - when mutated or expressed at high levels, they can help turn a normal cell into a tumor cell. Promising new chemotherapeutic strategies have therefore focused on suppressing oncogenes. One such approach is based on RNA interference (RNAi), a technique wherein small double-stranded RNA molecules can sequence-specifically inhibit the expression of targeted oncogenes. The idea here is that with the help of small interfering RNA (siRNA), key oncogenes that modulate signaling pathways and thereby regulate the behavior of malignant tumor cells can be manipulated. To harness the full potential of this approach, the prime requirements are to deliver the siRNA molecules with high selectivity and efficiency into tumor cells and to monitor both siRNA delivery and the resulting knockdown effects at the single-cell level.